The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Russia's premier cryptocurrency miner, BitRiver, faces insolvency proceedings as its CEO is placed under house arrest, marking a dramatic fall for a firm already crippled by international sanctions and mounting legal disputes.
As Bob Iger prepares to step down, he highlights a 'healthy competition' between Disney's resurgent parks and its entertainment division to become the company's primary profit driver, with the board close to naming his successor.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF (QDPL) has shifted from quarterly to monthly distributions, utilizing S&P 500 dividend futures to amplify its yield. This strategic pivot addresses investor demand for regular cash flow, though it introduces variability tied to derivatives markets.
A pivotal week for markets unfolds as Amazon, Alphabet, AMD, and Disney headline a packed earnings calendar. With implied volatility spiking, option traders brace for significant moves across sectors.
The death of Jose 'Gonzalito' Sanchez, second-in-command of Colombia's largest criminal syndicate, in a boating accident raises immediate questions about the stability of ongoing government negotiations aimed at ending decades of conflict.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.
Needham raises Nova Ltd. (NVMI) to Buy with a $500 price target, citing improving industry conditions and the company's strategic position in China's memory market. The upgrade follows a similar bullish move by Bank of America earlier in January.
Africa's used vehicle market is on track to expand at nearly 7% annually, approaching a $200 billion valuation by 2033, as demand for affordable personal transport surges across the continent.
Devon Energy announces plans to move its headquarters from Oklahoma City to Houston after finalizing its merger with Coterra Energy, while pledging to retain a substantial operational footprint in its longtime home state.
The $12 trillion asset manager founded by Jack Bogle announced another round of expense reductions across 53 funds, saving investors an estimated $600 million over two years and reinforcing its half-century mission of driving down costs for the everyday investor.
The Invesco NASDAQ-100 Equal Weight ETF (QQEW) has executed a dramatic portfolio shift, halving its holdings from 101 to 50 companies. This strategic pivot from pure equal-weighting to a quality-filtered approach aims to mitigate the risks of extreme concentration in the tech-heavy index while maintaining its core diversification ethos.
As housing costs squeeze employees nationwide, a new wave of benefits is emerging. Fintech startup Oro has raised $3 million to help employers offer housing assistance, signaling a major shift in corporate wellness strategies.
